<DOC>
	<DOCNO>NCT00572923</DOCNO>
	<brief_summary>Our group show omission elective nodal irradiation basis CT scan patient LD-SCLC lead higher expect isolated nodal recurrence ipsilateral supraclavicular area . We previously also show selective mediastinal nodal radiation basis FDG-PET scan NSCLC safe reduces radiation field hence toxicity . As accuracy FDG-PET scan also SCLC high CT , investigate safety selective nodal irradiation LD-SCLC patient treat concurrent chemo-radiation .</brief_summary>
	<brief_title>Concurrent Chemo-Radiotherapy Limited Disease Small Cell Lung Cancer ( LD-SCLC ) Basis FDG-PET-Scans</brief_title>
	<detailed_description>Eligible patient ( see ) receive radiotherapy primary tumor initially involve mediastinal lymph node FDG-PET scan dose 45 Gy 30 fraction 3 week ( 1.5 Gy BID minimum 6 h interfraction interval ) . Dose-constraints : MLD &gt; 20 Gy . In case , CT-based replanning do 1 week treatment shrink field technique use appropriate . The radiation dose specify accord ICRU 50 . Lung density correction apply , well standard QA procedure . Technical requirement standard practice MAASTRO clinic . Radiotherapy shall start first cycle carboplatin etoposide chemotherapy . Chemotherapy ( standard schedule Comprehensive Cancer Centre Limburg region ) : - carboplatin AUC 5 day 1 - etoposide 120 mg/m2 day 1-3 Q 3 week ; 5 cycle In patient progression WHO PS 0-2 , completion chemotherapy , PCI give ( 25 Gy 10 fraction , QD )</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<criteria>Histological cytological proven SCLC UICC stage IIII , `` limited disease '' Performance status 02 FeV 1 DLCO least 30 % agepredicted value Not SCLC mixed SCLC histology ( e.g . nonsmall cell lung carcinoma ) UICC stage IV Performance status 3 FeV 1 DLCO &lt; 30 % agepredicted value</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>radiotherapy</keyword>
	<keyword>LD-SCLC</keyword>
	<keyword>stage I-III small cell lung cancer</keyword>
</DOC>